
Top-line Results of a Phase 2, Double-blind, Randomized, Placebo-Controlled Study of a Reversible B Cell Inhibitor, XmAb[®]5871, in Systemic Lupus Erythematosus (SLE)

Joan T. Merrill¹ Joshua June², Fotios Koumpouras³, Wambui Machua⁴, Mohammed F. Khan⁵, Anca A. Askanase⁶, Arezou Khosroshahi⁷, Saira Z. Sheikh⁸, Paul Foster⁹, Debra J. Zack⁹ ¹Oklahoma Medical Research Foundation, ²Great Lakes Ctr. Of Rheumatology, ³Yale University, ⁴Piedmont Atlanta Hospital, ⁵Arthritis and Research Ctr. Of Oklahoma, ⁶Columbia University, ⁷Emory University, ⁸University of North Carolina at Chapel Hill, ⁹Xencor, Inc.

Introduction:

Antigen activated B cells are down-regulated by engagement of immune complexes with the inhibitory Fcv receptor FcvRIIb on the B cell surface. XmAb5871, an anti-CD19 mAb, has been engineered to enhance binding to FcyRIIb. The co-ligation of the B cell receptor associated membrane protein CD19 and FcyRIIb by XmAb5871 results in inhibition of many activation pathways in both healthy and disease B cells and in potent suppression of B cell responses without destroying B cells.



Objectives:

Primary Objective:

To determine the ability of XmAb5871 to maintain SLE disease activity improvement achieved by a brief course of disease-suppressing IM steroid therapy in SLE patients.

Secondary Objectives:

To evaluate time to loss of SLE disease activity improvement achieved by a brief course of diseasesuppressing IM steroid therapy in SLE patients

To evaluate the safety and tolerability of every other week IV administration of XmAb5871 in patients with SLE.

To evaluate the pharmacokinetics (PK) and immunogenicity of every other week IV administration of XmAb5871 in patients with SLE

Exploratory Objectives:

To characterize PD effects on absolute B cell count, autoantibodies, complement and cytokine levels over time.


Patient Population:

Male and female patients ages 18 to 65 inclusive with active SLE at screening. Patients had to stop all immunosuppressant agents by randomization, but were allowed to remain on hydroxychloroquine and prednisone equivalent of 10 mg or less per day. Patients could not have organ threatening disease.

Study Design:

Phase 2 randomized, double-blind, placebo-controlled study of approximately 100 patients with active SLE

Patients had to have moderate to severe non-organ threatening SLE activity defined as either a SELENA SLEDAI of ≥ 6 (≥ 4 points of which must come from non-serological finding) OR \geq 1 BILAG B OR \geq 1 BILAG A score. 104 SLE patients were enrolled to receive 5.0 mg/kg IV infusions of XmAb5871 14 days apart for 16 doses. Patients remained in study for up to 225 days with dosing given until LOI was apparent or through Day 211 (2 weeks prior to Day 225).



Background immunosuppressants XmAb5871 q2wk IV

Domographics

Up to 8 months treatmen

Demogi	apriles.		
		XmAb5871 (N=52)	Placebo (N=52)
Age	Years, median (range)	45.5 (23 - 65)	43.5 (20-64)
Sex	Female	50 (96.2%)	49 (94.2%)
Race	White Black Asian American Indian or Alaska Native Other	19 (36.5%) 26 (50.0%) 2 (3.8%) 2 (3.8%) 3 (5.8%)	25 (48.1%) 25 (48.1%) 1 (1.9%) 1 (1.9%) 0
Screening SLE Activity	Baseline BILAG, median (range) Baseline SLEDAI, median (range)	17 (8, 28) 8 (4, 16)	16 (9, 32) 10 (2, 18)

Disposition:

	XmAb5871 (N=52)	Placebo (N=52)
Completed the Study to Day 225	28 (53.8%)	17 (32.7%)
Reasons for Early Discontinuation:		
Loss of Improvement	14 (58.3%)	25 (71.4%)
Adverse Event *	7 (29.2%)	
Withdrawal	3 (8.6%)	10 (21.1%)

* Includes 6 XmAb-treated patients that had infusion-related events on the first dose and withdrew from the study due to intolerance to medication.

Stop XmAb5871/placebo

Safety:

TEAEs:

531 TEAEs were reported in 85 patients. Of those, 149 events in 41 patients were considered to be drug-related (26% in the placebo arm). The vast majority of TEAEs were mild or moderate in severity. The most common AEs seen in >5% of patients are shown below:

XmAb5871-04 TEAEs in > 5% of Patients				
	XmAb5871		Placebo	
	(N=52)		(N=52)	
TEAE (MedDRA)	All TEAE, n (%)	Related TEAE n(%)	All TEAE, n (%)	Related TEAE, n(%)
Nausea	20 (38.5)	14 (26.9)	9 (17.3)	5 (9.6)
Headache	12 (23.1)	6 (11.5)	1 (1.9)	
Muscle spasms	5 (9.6)	3 (5.8)	6 (11.5)	1 (1.9)
Back pain	8 (15.4)	5 (9.6)	2 (3.8)	
Upper respiratory tract infection	4 (7.7)		6 (11.5)	
Vomiting	9 (17.3)	9 (17.3)	1 (1.9)	
Dizziness	8 (15.4)	3 (5.8)	1 (1.9)	
Cough	4 (7.7)	2 (3.8)	4 (7.7)	1 (1.9)
Diarrhoea	4 (7.7)	1 (1.9)	4 (7.7)	1 (1.9)
Urinary tract infection	5 (9.6)		3 (5.8)	
Flushing	7 (13.5)	4 (7.7)	0 (0.0)	
Nasopharyngitis	4 (7.7)		3 (5.8)	
Pain in extremity	6 (11.5)		1 (1.9)	
Abdominal pain	5 (9.6)	2 (3.8)	1 (1.9)	
Abdominal pain upper	3 (5.8)	3 (5.8)	2 (3.8)	1 (1.9)

SAEs:

13 SAEs were reported in 11 subjects in the study:

• XmAb5871: Fever, SLE flare (lung), Atrial fibrillation, Worsening hypertension, Iron deficiency anemia, Pneumonia (36 days after last dose [10 half-lives]), Infusion related reaction, Vertigo • Placebo:

Anemia SLE flare, SLE flare (enteritis), angioedema, migraine headache

- All SAEs were considered Not or Unlikely Related except the infusion related reaction.
- There were no deaths and no opportunistic infections.

Analysis:

Analysis Populations			
Efficacy Evaluable	All subjects who completed Day 225, had LOI, or discontinued due to a drug-related adverse event Excludes 12 treated subjects who discontinued early with no LOI and no toxicity (2 XmAb, 10 placebo)		
Intent to Treat	All subjects that received a partial dose of XmAb5871 or placebo		
Day 169 Efficacy	Original 6-month endpoint		


Primary Endpoint:


The primary endpoint was Loss of Improvement a Day 225 in the Efficacy Evaluable Population was not statistically significant (p = 0.18). However, the first secondary endpoint of time to loss of improvement was significant (p = 0.025).

		XmAb5871 (N=50)	
Response Rate (No loss of improvement through Day 225)	n (%)	21 (42.0)	
95% Confidence Interval		(28.2, 56.8)	
Non-Responder	n (%)	29 (58.0)	
Loss of improvement at any visit	n (%)	23 (46.0)	
Early discontinuation for toxicity (assigned non-responder status)	n (%)	6 (12.0)	

Secondary Endpoints:

Time to Loss of Improvement Thru Day 225 Planned Visit – Efficacy Evaluable






Other Secondary Endpoints: Maintenance of Improvement				
	Efficacy Evaluable Population			
	XmAb5871	Placebo	p value	
% Response at Day 169	58	40.5	0.11	
	Intent to Treat Population			
	Intent to	Treat Popu	lation	
	Intent to XmAb5871	Treat Popu Placebo	lation p value	
% Response at Day 225		•		

Median Time on Treatment and Number of Infusions Received			
		XmAb5871 (N=52)	Placebo (N=52)
Time on Treatment	Months, median (range)	6.9 (0.0 – 7.4)	3.6 (0 – 7.0)
Number of Infusions	Median (range)	15 (1 – 16)	8.5 (1 – 16)

Conclusions:

- Positive trend in primary endpoint, proportion of efficacy-evaluable patients who did not experience loss of improvement (LOI) by Day 225, but did not meet statistical significance (XmAb5871 42% vs. placebo 28.6%, p = 0.18)
- Median time to LOI (a secondary endpoint) was extended by 76% for patients treated with XmAb5871 (median 230 days vs. 131 days for patients on placebo, hazard ratio = 0.53, p = 0.0252)
- XmAb5871-treated patients remained without increase in disease activity and on study longer than the placebo patients.
- Risk of increased SLE disease activity was reduced by 47% for patients treated with XmAb5871 (median 230 days vs. 131 days for patients on placebo, hazard ratio = 0.53, p = 0.0252)
- XmAb5871 well-tolerated and safety profile consistent with previous studies, except for discontinuations from infusion reactions. In order to avoid the infusion reactions, a subcutaneous formulation will be used in future studies. Bioavailability studies with the SC drug showed no infusion reactions or GI-related infusion reactions in a healthy population of 40 subjects.



Time to Loss of Improvement Thru Day 225 Planned Visit – Intent to Treat